Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines

Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in...

Descripción completa

Detalles Bibliográficos
Autores principales: Namatame, Nachi, Tamaki, Naomi, Yoshizawa, Yuya, Okamura, Mutsumi, Nishimura, Yumiko, Yamazaki, Kanami, Tanaka, Miwa, Nakamura, Takuro, Semba, Kentaro, Yamori, Takao, Yaguchi, Shin-ichi, Dan, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205545/
https://www.ncbi.nlm.nih.gov/pubmed/30416685
http://dx.doi.org/10.18632/oncotarget.26216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205545/
https://www.ncbi.nlm.nih.gov/pubmed/30416685
http://dx.doi.org/10.18632/oncotarget.26216

Ejemplares similares